

Supplementary

Table S1 Vancomycin dose and C_{trough} measurement between vancomycin loading dose (LD) and non-LD groups in subgroup analysis with patients who had creatinine clearance (CrCl) of >30 mL/min and were matched by CrCl

Characteristics	LD group (n=20)	Non-LD group (n=20)	P value
CrCl by Cockcroft-Gault	87.9 (57.4–112.9)	84.6 (56.7–112.9)	0.947
First dose of vancomycin			
Median dose per weight, mg/kg	24.5 (22.3–25.8)	14.9 (12.7–18.7)	<0.001
Groups by median dose per weight, mg/kg			
<15	0 (0.0)	10 (50.0)	<0.001
15–20	2 (10.0)	7 (35.0)	
20–25	12 (60.0)	3 (15.0)	
25–30	5 (25.0)	0 (0.0)	
>30	1 (5.0)	0 (0.0)	

Values are median with interquartile range or n (%).

Table S2 Proportion of pharmacokinetic target (trough concentration ≥ 15 mg/L) attainment between vancomycin loading dose (LD) and non-LD groups in subgroup analysis with patients who had creatinine clearance (CrCl) of >30 mL/min and were matched by CrCl

Characteristics	LD group (n=20)	Non-LD group (n=20)	P value
Time to target attainment, h	48 (24–108)	42 (24–93)	0.845
Target attainment within 24 h	6 (31.6)	8 (44.4)	0.420
Target attainment within 48 h	10 (52.6)	10 (55.6)	0.858

Values are median with interquartile range or n (%). OR, odds ratio; CI, confidence interval.

Table S3 Clinical outcomes between vancomycin loading dose (LD) and non-LD groups in subgroup analysis with patients who had creatinine clearance (CrCl) of >30 mL/min and were matched by CrCl

Outcomes	LD group (n=20)	Non-LD group (n=20)	OR (95% CI)	P value
Clinical cure	14 (70.0)	12 (60.0)	1.56 (0.42–5.76)	0.507
Microbiological cure	14 (70.0)	17 (85.0)	0.41 (0.09–1.95)	0.451
ICU mortality	4 (20.0)	4 (20.0)	1.00 (0.21–4.71)	>0.999
90-day mortality	8 (40.0)	5 (25.0)	2.00 (0.52–7.72)	0.311
Adverse drug reaction	9 (45.0)	7 (35.0)	1.52 (0.43–5.43)	0.519
Acute kidney injury	9 (45.0)	7 (35.0)	1.52 (0.43–5.43)	0.519

OR, odds ratio; CI, confidence interval; ICU, intensive care unit.